Positron emission tomography (PET) is an extraordinarily sensitive clinical imaging modality for interrogating tumor metabolism. Radiolabeled PET substrates can be traced at subphysiological concentrations, allowing noninvasive imaging of metabolism and intratumoral heterogeneity in systems ranging from advanced cancer models to patients in the clinic. There are a wide range of novel and more established PET radiotracers, which can be used to investigate various aspects of the tumor, including carbohydrate, amino acid, and fatty acid metabolism. In this review, we briefly discuss the more established metabolic tracers and describe recent work on the development of new tracers. Some of the unanswered questions in tumor metabolism are considered alongside new technical developments, such as combined PET/magnetic resonance imaging scanners, which could provide new imaging solutions to some of the outstanding diagnostic challenges facing modern cancer medicine.
A wide range of new and classic PET radiotracers have been used in preclinical and clinical investigations, and although it is unlikely that many of these new agents will transfer into routine clinical practice, it is nevertheless plausible some of them will be useful for clinical decision making in the future. 10 The majority will most likely be used in a research setting, ideally in combination with other imaging modalities such as magnetic resonance imaging (MRI), to better understand cancer metabolism 11 and to facilitate the drug development process by giving an early indication of drug efficacy in early-stage clinical trials. 2, 7, 12 A list of some metabolic PET tracers, classed by the metabolic pathway that they interrogate, is shown in Table 1 . A comprehensive molecular imaging tracer database is available online from the NCBI. 13 In this review, we will briefly present the classic metabolic PET tracers and describe recent work on the development of new tracers.
CARBOHYDRATE UTILIZATION AND STORAGE
Indisputably the most important PET tracer for imaging tumor metabolism is 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG). It is over 3 decades since the first images of a tumor accumulating FDG were published, 14 and FDG remains the archetypal PET tracer for tumor characterization, staging, and response evaluation. Tumors, unlike normal tissues, show high rates of aerobic glycolysis, which, as well as providing ATP, also provides glycolytic intermediates that are used in anabolic pathways for the synthesis of amino acids, lipids, nucleotides, and NADPH. 15 FDG is widely recognized as a tracer for imaging the Warburg effect in cancer 16 that is up-regulated glucose utilization in the presence of oxygen, where the pyruvate generated by the glycolytic pathway is not oxidized in the mitochondria but rather reduced to lactate. 17, 18 Although it seems inconceivable that the dominance of FDG as the PET agent for tracing cancer carbohydrate metabolism will be surpassed, not all tumors are FDG avid, and FDG is not always cancer specific; for example, there can be increased FDG uptake in inflammation. 19 A number of attempts have been made to develop 18 F-labeled PET analogs from other sugars, including D-mannose, 20 D-lactose, 21 D-fructose, 22 and D-galactose. 23 Of these, 1-[ 18 F]fluoroethyl-β-Dlactose (FEL) has shown promise in delineating peritumoral regions of pancreatic cancer that overexpress hepatocarcinoma-intestinepancreas/pancreatitis-associated protein (HIP/PAP). 21 [ 18 F]FEL binds to the carbohydrate-binding domain of HIP/PAP with higher affinity than other sugars, and HIP/PAP is highly overexpressed in the peritumoral region compared with normal pancreas and chronic pancreatitis. 24,25 6-Deoxy-6-[ 18 F]fluoro-D-fructose ([ 18 F]FDF) is transported into the cell by the glucose transporter, GLUT-5, and subsequently phosphorylated by a ketohexokinase, unlike FDG, which is transported predominantly by GLUT-1 and GLUT-3 in tumors and phosphorylated by hexokinase. 22, 26 [ 18 F]FDF therefore detects a pathway that is distinct from that used by glucose and that may predominate in some forms of breast cancer, 22 although the role of GLUT-5 in cancer is not yet established. 27 FDG reports on the first 2 steps in the glycolytic pathway: plasma membrane transport and subsequent phosphorylation by hexokinase. 28 A novel probe for imaging glycogen metabolism (glycogenesis) has been described recently that reports on several steps in the glycogen synthesis pathway. 29 Uptake of [ 18 F]-N-(methyl-(2-fluoroethyl)-1H- [1, 2, 3] triazole-4-yl) glucosamine ([ 18 F]NFTG) was determined principally by glycogen synthase 1 levels, which were shown to be high during cellular quiescence. 30 The mechanism responsible for tracer accumulation remains to be elucidated; however, a possible route is via galactokinase 1 (GALK1), galactose 1-phosphate uridylyltransferase (GALT), UDP-galactose epimerase (GALE), and glycogen synthase 1 (GYS1). 31 The pentose phosphate pathway (PPP) is an important component of cellular carbohydrate metabolism, responsible for the synthesis of nucleotides and the generation of biosynthetic reducing power in the form of NADPH. However, the complex regulation of the PPP in cancer is still not fully understood. 32 The recent development of [ 18 F]-2-deoxy-2-fluoroarabinose has shown that this modified ribose is transported by GLUT-2, phosphorylated by ribokinase, and further metabolized by transketolase, the latter being a key enzyme in the PPP. Although developed as a probe of the ribose salvage pathway, this radiotracer may also prove useful for studying aspects of PPP activity in vivo. 33 
AMINO ACIDS
Numerous amino acids have been radiolabeled for imaging flux through various amino acid transporters and in some cases FIGURE 1 . A schematic of the metabolic pathways and enzymes responsible for the intracellular trapping of key PET substrates for imaging cancer metabolism. Radionuclides and PET substrates are shown in red. Note the localization of hexokinase 2 (HK2) to the mitochondria. 16 When the tumor cell activates aerobic glycolysis, HK2 can bind to the anion transporter channel on the outer mitochondrial membrane (VDAC), preferentially gaining access to mitochondrially generated ATP. 117 ACLY indicates ATP citrate lyase; ACSS2, acetyl coA synthetase short-chain family member 2, cytosolic; ASCT2 -neutral amino acid transporter (SLC1A5); Ala, alanine; CPT1, carnitine palmitoyl transferase I; CTL, choline transporter-like proteins (SLC44A); Cys, cysteine; FATP, FA transport protein ; Gal, galactose; GALK1, galactokinase 1; GLS1, glutaminase 1; Gluc, glucose; Gln, glutamine; Glu, glutamate; GLUT, glucose transporter; GYS1, UDP-glucose-glycogen glucosyltransferase; HK2, hexokinase 2; LAT1, L-type amino acid transporter 1 (SLC7A5); LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; SNAT, system A amino acid transporter; X C − , anionic amino acid transporter light chain, system x c − (SLC7A11); TCA, tricarboxylic acid cycle.
for measuring protein synthesis. 3 Protein synthesis rates have been measured in muscle using [ 11 C]methionine, 34 in normal brain using [ 11 C]leucine, 35 in soft tissue sarcoma 36 and pituitary adenoma 37 using [ 11 C]tyrosine, and in glioma using [ 11 C]tyrosine and [ 11 C]methionine. 4, 38 Radiolabeled unnatural amino acids can be used to visualize amino-acid transporter activity specifically as they are not recognized by aminoacyl-tRNA synthetases and therefore not incorporated into proteins. 3 Numerous amino acid transporter subtypes have been described with varying substrate specificities (denoted as type A, B 0 , N, ASC, X-AG, L, y + , y + L, x c − ). Typical tracers include L-type amino acid transporter substrates such as [ 18 F]fluoroethyltyrosine ([ 18 F]FET) and [ 18 F]dihydroxy-phenyl-alanine ([ 18 F]FDOPA), 39, 40 which have been used for cancer diagnosis and for monitoring treatment response in tumors that are difficult to image with FDG, especially brain tumors. L-type amino acid transporter 1 (LAT1) expression is increased in glioma and many other cancers and is associated with high grade and poor prognosis. [41] [42] [43] [44] [ 18 F]FET has been reported to be useful not only for visualizing tumors, but also for grading, monitoring treatment response, and differentiating pseudoprogression from early treatment failure in glioblastoma. [45] [46] [47] Recently, efforts have been made to radiolabel substrates of other amino acid transporters, in addition to LAT1. ASCT2, like LAT1, is an obligatory amino acid exchanger whose expression is prognostic in pancreatic and non-small cell lung cancer (NSCLC). 48, 49 ASCT2 and LAT1 may cooperate during malignant ACSS2acetyl coA synthetase short-chain family member 2, cytosolic; ASCT2 -neutral amino acid transporter (SLC1A5); ATB 0,+ -amino acid transporter ATB0 (SLC6A14); ChoKcholine kinase; ChOcholine oxidase; EAATexcitatory amino-acid transporter; GLUTglucose transporter; GYS1 -UDP-glucose-glycogen glucosyltransferase; HIP/PAPhepatocarcinoma-intestine-pancreas/pancreatitis-associated protein; HKhexokinase; KHKketohexokinase; LAT1 -L-type amino acid transporter 1 (SLC7A5); ODCornithine decarboxylase; PEPT1 -Peptide transporter 1 (SLC15A1); SMITsodium/myo-inositol transporter; SNATsystem A amino acid transporter; X C −anionic amino acid transporter light chain, system x c − (SLC7A11)
The Cancer Journal • Volume 21, Number 2, March/April 2015 Imaging Tumor Metabolism Using PET transformation to generate an influx of glutamine, and other amino acids, for the biosynthetic processes that support tumor growth and cancer cell survival. 50 The leucine analog trans-1-amino-3-[ 18 F]fluorocyclobutanecarboxylic acid (FACBC) is transported by ASCT2 and LAT1 and has shown high tumor uptake and low bladder excretion in a number of clinical studies of prostate cancer. 51, 52 System A amino acid transporters (SNAT1, SNAT2, and SNAT4) are electrogenic and concentrative and therefore potentially attractive targets for PET. The recently described agents (R)-and (S)-3-[ 18 F]fluoro-2-methyl-2-N-(methylamino)propanoic acid ([ 18 F]FMeAMP) are transported predominantly by A-type amino acid transporters and showed up to 115 times more uptake in 9L rat glioma cells compared with normal brain. However, this ratio was enhanced by a lack of type A transporters on the luminal membranes of blood vessels in normal brain (in the tumor, there is breakdown of the blood-brain barrier [BBB] 53 ), and therefore [ 18 F]FMeAMP uptake in the glioma measures predominantly BBB breakdown rather than cerebral amino acid uptake per se. The tracer may be more suitable therefore for tumors originating at other sites. Uptake of [ 18 F]FMeAMP was recently observed in breast, NSCLC, and prostate and ovarian cancer xenografts. 54 Three new tracers that are specific for system x c − transporters have been described: 18 58 with uptake of the latter demonstrated in hepatocellular carcinoma 59 and in NSCLC and breast cancer patients. 60 System x c − is an electroneutral cystine/ glutamate antiporter. System x c − activity directly regulates the concentration of glutathione, an intracellular antioxidant peptide, as uptake of cystine and its subsequent reduction to cysteine are rate-limiting steps for glutathione synthesis. 61 System xc − is up-regulated under conditions of oxidative stress, which increases glutathione production and protects the cell from oxidative damage. 62 Because chemoresistant cancer stem cells stabilize system x c − activity, increasing their capacity to withstand oxidative stress, 63 imaging system x c − activity may be predictive of resistance to treatment. 62 Some tumors use glutamine preferentially for anaplerosis and energy production (glutaminolysis), which can be activated by oncogenic myc signaling. 17, 64 A series of PET tracers have been designed to image glutaminolysis including L-[5-11 C]-glutamine, 65 
FATTY ACIDS
Fatty acids are major substrates for catabolic and anabolic processes; cancer cells often show high levels of lipid droplet formation, 70 FA oxidation, 71 and de novo FA synthesis. 72 Fatty acids, labeled with both 11 C and 18 F, have been developed as PET tracers, mostly for studying β-oxidation. 73 The most promising of these are the thia-substituted FAs, which incorporate sulfur in position 4 of the FA carbon chain. 74 These exhibit metabolic stability and trapping subsequent to their commitment to mitochondrial FA oxidation. Of these, 18-[ 18 F] fluoro-4-thia-oleate (FTO) showed the highest uptake in the protein-bound fraction in heart, liver, and muscle mitochondria. 75 The proposed mechanism for cell accumulation is via entry on the FA transport protein, esterification to produce FTO-CoA, and trans-esterification to FTOcarnitine (catalyzed by CPT-1). Subsequent trapping inside the mitochondria occurs after 2 steps of β-oxidation and spontaneous decomposition to 14-[ 18 F]fluoro-tetradecane-1-thiol, which binds covalently or noncovalently to various mitochondrial proteins. In obese individuals, increased FA flux from visceral fat to hepatic oxidation was demonstrated using dynamic PET measurements with [ 11 C]palmitic acid. 73 Tumor cells show increased de novo FA synthesis, which is required for rapid proliferation and cell survival. 76 Fatty acid synthase (FASN), a key enzyme in this pathway, has recently come into focus as a potential therapeutic target in cancer. 77, 78 [ 11 C] acetate can be used to monitor de novo FA synthesis in mice, 5, 6, 79 and translational studies are ongoing to assess its utility in humans. The major drawback of [ 11 C]acetate as a tracer for monitoring FASN activity is that it is used in both the oxidative and FA synthesis pathways 77, 78 and the half-life of 11 C (t ½ = 20.4 minutes) may be too short to detect the synthesis component. Attempts have been made to develop a radiotracer labeled with the longer-lived radionuclide fluorine-18 (t ½ = 109.8 minutes). The closest analog [ 18 F]fluoroacetate has been studied in vivo 80 ; however, it did not trace the FA synthesis pathway and therefore cannot be used for FASN activity monitoring. 81 Whether another short-chain FA 2-[ 18 F]fluoropropionate is a tracer of de novo FA synthesis remains to be determined, but initial studies in prostate tumor xenografts demonstrated high tumor retention. 82 [ 18 F] fluoropivalic acid was initially developed as a tracer for FA synthesis 83 ; however, its accumulation in murine breast adenocarcinoma cells as the carnitine ester ruled it out as a FA synthesis tracer and instead suggested a potential role as a probe of FA β-oxidation. 84 [ 11 C]choline and the fluorinated analogs [ 18 F]fluoromethylcholine and [ 18 F]fluoroethylcholine have been used extensively for imaging several malignancies but primarily for detection of prostate cancer. 85, 86 The mechanism of choline accumulation in tumors is not fully understood and might reflect either the activity of the de novo phosphatidylcholine synthesis (Kennedy) pathway or oxidative metabolism via the betaine-sarcosine-glycine pathway, which was shown recently to be highly active in prostate cancer. 87, 88 To simplify its metabolic profile, deuterated versions of radiolabeled choline were developed in order to reduce betaine oxidation while preserving phosphorylation and entry into the Kennedy pathway. 89, 90 Clinical translation may provide additional insight into the nature of malignant transformation in prostate cancer, with first-in-man studies reported recently. 91 
UNANSWERED QUESTIONS IN TUMOR METABOLISM
Metabolic reprogramming is one of the hallmarks of cancer, and yet the metabolic niches within the tumor microenvironment are still not well understood. 92 There are a number of unanswered questions in cancer metabolism such as the extent of glutaminolysis, 17 glycine dependence, 93 metabolic symbiosis, 94 and de novo purine synthesis. 95 Tumors can utilize various substrates, 96 including acetate, 78 lactate, 97 glycine, 93 glutamine, 98 and proline. 99 How does the utilization of these substrates vary between different tumor types, and does this confer susceptibility or resistance to certain kinds of therapy? Some insight into these questions could be gained by quantitative PET imaging, which requires dynamic imaging with arterial metabolite-corrected plasma concentrations as an input function for a well-designed compartmental model. 100 Many of these mathematical models were designed for neuroscience applications, where the BBB tends to exclude circulating radiometabolites. Their use in cancer may require double input functions to control for radiometabolites that reenter the tumor. 8, 101 Although the energy of the emitted positrons may vary between different radionuclides, 2 PET tracers injected simultaneously cannot be distinguished in the same scan as the energy of the 2 γ-rays resulting from positron annihilation, which are what is detected in the PET scanner, are a constant at 511 keV. Therefore, measurements with dual radiotracers need to be performed sequentially. One possibility would be to use a single PET tracer for measuring several distinct processes. For example, in separate studies, [ 11 C]acetate has been used with modeling approaches to measure blood flow, 102 oxidation, 103 and FA synthesis, 5, 104 all of which are altered within a tumor and potentially provide prognostic information.
One of the challenges will be in validating new tracers as few complementary techniques are available. One possibility would be to measure uptake and flux through a particular pathway with the same substrate labeled in different preparations with 11 C and hyperpolarized 13 C. [105] [106] [107] These could be imaged simultaneously with magnetic resonance spectroscopic imaging and PET in a combined PET/MRI scanner. 108 In addition to the logistical challenges of such an experiment, it requires a substrate that can be radiolabeled with sufficient yield and specific activity that also has the right attributes for hyperpolarization. Dual PET/MRI can provide complementary information, enhancing the information content of both imaging modalities. For example, arterial input functions can be derived from dynamic contrast enhanced MRI, which may be extrapolated to dynamic PET data providing an alternative to arterial sampling. 109 In an implanted colon tumor model, increased cell proliferation, determined using PET measurements of [ 18 F]FLT uptake, were correlated with regions of increased perfusion, detected using dynamic contrast agentenhanced MRI. 108 Preclinical imaging studies have been conducted largely in subcutaneous or orthotopic cancer cell line models, usually because of convenience and cost. However, these models only recapitulate certain aspects of tumor development and may not always be relevant to the clinic. The capability of preclinical imaging to answer questions about tumor biology would be much improved by the use of more advanced animal models. 110 These include spontaneous and conditional genetically engineered mouse models, tumors generated by somatic cell transduction, 111, 112 patient-derived xenografts, 113 embryonic stem cell chimeras, 114 and orthotopically implanted organoids, 115 which can better capture the heterogeneity and diversity of human cancers. 116 Recent years have seen the development of several novel substrates for PET that has added substantially to the arsenal of more established radiotracers for imaging tumor metabolism. Although many of these may not translate into routine clinical use, they will undoubtedly have a role to play in experimental investigations of tumor cell metabolism and also in the drug development process, where they may be useful in making go/no-go decisions in early-stage clinical trials. For the more established radiotracers that are already in use, particularly FDG, there may be significant benefits in combining PET with other imaging modalities. Positron emission tomography/computed tomography is already widely used, and the use of PET/MRI is increasing, where metabolic imaging with PET can be combined with the numerous contrast mechanisms available in MRI to ask more specific questions about the regional metabolism of tumors. For example, low FDG uptake in a part of a tumor may indicate a low viable cell density or low FDG uptake by tumor cells in that region. Diffusion-weighted MRI, which can be used to estimate cell density, could potentially answer this question. 2 
